Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor

Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor

Blog Article

Abstract The prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) is dismal, with surgical resection being the only definitive salvage therapy.Treatment with chemoradiation approaches has not significantly improved patient outcomes.Similarly, trials of therapies targeting MPNST genomic drivers have thus far been unsuccessful.Improved understanding of the molecular pathogenesis ribavirin coupon of MPNST indicates frequent activation of the mitogen-activated protein kinase (MAPK) cell signaling pathway.

MEK inhibitors have shown activity in preclinical studies; however, their clinical efficacy has not been reported to date.We describe here a case of sustained complete response to airpods in jacksonville MEK inhibition in an adolescent patient with a recurrent metastatic MPNST with multiple alterations in the MAPK pathway, guided by a precision oncology approach.